Rigel Pharmaceuticals
RIGL
Market Cap$335.46M
Close$
$-10.27
154.7% downside
Current Fair Value
154.7% downsideOvervalued by 154.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $335.46 Million |
|---|---|
| Enterprise Value | $366.48 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.99 |
| Beta | 1.34 |
| Outstanding Shares | 17,647,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 18.94 |
|---|---|
| PEG | -5.95 |
| Price to Sales | 2.35 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.33 |
| Enterprise Value to EBIT | 36 |
| Enterprise Value to Net Income | 94 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 26.69 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Rigel Pharmaceuticals
CEO: Raul Rodriguez